Jackson Grant Investment Advisers Inc. Buys 78 Shares of Johnson & Johnson $JNJ

Jackson Grant Investment Advisers Inc. boosted its stake in Johnson & Johnson (NYSE:JNJ) by 0.6% in the second quarter, HoldingsChannel reports. The institutional investor owned 13,048 shares of the company’s stock after buying an additional 78 shares during the quarter. Johnson & Johnson accounts for approximately 0.7% of Jackson Grant Investment Advisers Inc.’s portfolio, making the stock its 26th biggest position. Jackson Grant Investment Advisers Inc.’s holdings in Johnson & Johnson were worth $1,993,000 as of its most recent SEC filing.

A number of other hedge funds have also recently bought and sold shares of the company. Brighton Jones LLC grew its stake in Johnson & Johnson by 13.9% in the 4th quarter. Brighton Jones LLC now owns 51,876 shares of the company’s stock valued at $7,502,000 after purchasing an additional 6,332 shares during the period. Baker Tilly Wealth Management LLC raised its stake in shares of Johnson & Johnson by 38.4% during the 1st quarter. Baker Tilly Wealth Management LLC now owns 8,004 shares of the company’s stock worth $1,327,000 after purchasing an additional 2,221 shares during the period. Fiduciary Alliance LLC boosted its holdings in shares of Johnson & Johnson by 1.3% in the 1st quarter. Fiduciary Alliance LLC now owns 79,753 shares of the company’s stock worth $13,226,000 after buying an additional 1,015 shares during the last quarter. Worth Asset Management LLC grew its position in Johnson & Johnson by 49.0% during the first quarter. Worth Asset Management LLC now owns 2,391 shares of the company’s stock valued at $396,000 after buying an additional 786 shares during the period. Finally, Enterprise Bank & Trust Co increased its holdings in Johnson & Johnson by 3.6% during the first quarter. Enterprise Bank & Trust Co now owns 5,283 shares of the company’s stock worth $876,000 after buying an additional 185 shares during the last quarter. 69.55% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

JNJ has been the subject of a number of research reports. The Goldman Sachs Group increased their target price on shares of Johnson & Johnson from $185.00 to $186.00 and gave the company a “buy” rating in a research report on Friday, September 19th. Barclays upped their price objective on Johnson & Johnson from $165.00 to $176.00 and gave the company an “equal weight” rating in a research note on Thursday, July 17th. Royal Bank Of Canada boosted their target price on Johnson & Johnson from $181.00 to $185.00 and gave the company an “outperform” rating in a research note on Thursday, July 17th. Morgan Stanley increased their price target on Johnson & Johnson from $171.00 to $176.00 and gave the stock an “equal weight” rating in a research note on Thursday, July 17th. Finally, Bank of America boosted their price objective on Johnson & Johnson from $161.00 to $175.00 and gave the company a “neutral” rating in a research note on Thursday, July 17th. Two research analysts have rated the stock with a Strong Buy rating, ten have given a Buy rating and nine have given a Hold rating to the company’s stock. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average price target of $181.40.

Insider Activity

In other Johnson & Johnson news, EVP Jennifer L. Taubert sold 56,471 shares of the company’s stock in a transaction dated Thursday, September 4th. The shares were sold at an average price of $177.81, for a total transaction of $10,041,108.51. Following the completion of the sale, the executive vice president directly owned 178,013 shares in the company, valued at $31,652,491.53. This represents a 24.08% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. Company insiders own 0.16% of the company’s stock.

Johnson & Johnson Price Performance

JNJ stock opened at $181.63 on Tuesday. The firm has a 50 day simple moving average of $174.76 and a two-hundred day simple moving average of $162.18. The stock has a market cap of $437.43 billion, a PE ratio of 19.43, a P/E/G ratio of 2.29 and a beta of 0.40. Johnson & Johnson has a one year low of $140.68 and a one year high of $181.87. The company has a debt-to-equity ratio of 0.50, a current ratio of 1.01 and a quick ratio of 0.76.

Johnson & Johnson (NYSE:JNJ) last issued its quarterly earnings results on Wednesday, July 16th. The company reported $2.77 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.68 by $0.09. The firm had revenue of $23.74 billion during the quarter, compared to analyst estimates of $22.85 billion. Johnson & Johnson had a return on equity of 32.49% and a net margin of 25.00%.The company’s revenue was up 5.8% compared to the same quarter last year. During the same quarter in the previous year, the company posted $2.82 earnings per share. Johnson & Johnson has set its FY 2025 guidance at 10.800-10.900 EPS. On average, analysts predict that Johnson & Johnson will post 10.58 EPS for the current fiscal year.

Johnson & Johnson Announces Dividend

The firm also recently disclosed a quarterly dividend, which was paid on Tuesday, September 9th. Stockholders of record on Tuesday, August 26th were issued a $1.30 dividend. This represents a $5.20 dividend on an annualized basis and a dividend yield of 2.9%. The ex-dividend date was Tuesday, August 26th. Johnson & Johnson’s payout ratio is presently 55.61%.

Johnson & Johnson Company Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.